Xanomeline

FDA approves Cobenfy, a new schizophrenia treatment targeting cholinergic receptors, offering an alternative to traditional antipsychotic drugs.

FDA approved Bristol Myers Squibb's Cobenfy for schizophrenia, while Reviva's Brilaroxazine targets broader receptors, potentially offering cognitive benefits and a better metabolic profile. Both drugs address positive and negative symptoms of schizophrenia.

The FDA approved Cobenfy, a new schizophrenia treatment working via acetylcholine receptors, differing from traditional dopamine-modifying antipsychotics. Initial trials show symptom reduction, but long-term efficacy and side effects remain uncertain. Cobenfy aims to avoid common antipsychotic side effects like weight gain and movement disorders but may cause digestive issues and urinary retention. The drug's high cost and need for extended trials pose challenges.

Bristol Myers Squibb's schizophrenia drug, Cobenfy, approved by FDA after 30-year journey from Eli Lilly's Alzheimer's drug xanomeline, could inspire future drug discovery.

The FDA approved Cobenfy, a new oral drug by Bristol Myers Squibb, for schizophrenia, targeting a different neurotransmitter system than traditional antipsychotics. Cobenfy may alleviate symptoms like hallucinations and delusions without common side effects, potentially improving cognitive deficits and negative symptoms. Developed initially for Alzheimer’s, Cobenfy combines xanomeline and trospium chloride, offering hope for treatment-resistant schizophrenia and potentially revitalizing schizophrenia drug research.

The FDA approved Cobenfy (xanomeline and trospium chloride) for schizophrenia in adults, marking the first novel mechanism of action in over 30 years. Jelena Kunovac, involved in its clinical trials, highlights its unique approach and potential benefits for patients, emphasizing the need for clinicians to understand its adverse events before prescribing.

FDA approves Bristol Myers Squibb's Opdivo for resectable NSCLC, showing reduced disease recurrence risk by 42% and 18-month EFS in 70% of patients. Opdivo is the only PD-1 inhibitor with significant benefits over chemotherapy in neoadjuvant and perioperative regimens.

Recent news includes Pfizer’s withdrawal of Oxbryta, Vertex partnering with Lonza for Casgevy, Emergent BioSolutions’ $400 million BARDA contract for mpox vaccine, and Bristol Myers Squibb’s approval of Cobenfy for schizophrenia. Discussions also cover ARCH Ventures’ $3 billion biotech fund and Flagship Pioneering’s $3.6 billion raise, along with COVID-19-associated childhood myopia and patent thickets.

FDA approves Cobenfy® (xanomeline and trospium chloride) for schizophrenia, based on EMERGENT-2 and EMERGENT-3 trials showing significant PANSS score reductions. Common adverse reactions include nausea, dyspepsia, and hypertension.

FDA approves Bristol Myers Squibb's COBENFY (xanomeline and trospium chloride), a first-in-class muscarinic agonist for schizophrenia, targeting M1 and M4 receptors without blocking D2 receptors, offering a new treatment option.